DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration

Similar documents
2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process-High Priority

DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

NUMERATOR: All patients with a diagnosis of Parkinson s Disease who were assessed for cognitive impairment or dysfunction in the past 12 months

Quality ID #414: Evaluation or Interview for Risk of Opioid Misuse National Quality Strategy Domain: Effective Clinical Care

DESCRIPTION: Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient

Measure #408: Opioid Therapy Follow-up Evaluation National Quality Strategy Domain: Effective Clinical Care

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

DENOMINATOR: All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

DENOMINATOR: All patients undergoing anterior or apical pelvic organ prolapse (POP) surgery

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

DESCRIPTION: The percentage of adolescent females years of age who were screened unnecessarily for cervical cancer

DENOMINATOR: All female patients aged 65 years and older with a diagnosis of urinary incontinence

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Efficiency High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

DESCRIPTION: Percentage of patients with dementia for whom an assessment of functional status was performed at least once in the last 12 months

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient Reported Outcome High Priority

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process-High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Quality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

DENOMINATOR: All patients, regardless of age, with a diagnosis of inflammatory bowel disease who initiated an anti-tnf agent

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.

Quality ID #293: Parkinson s Disease: Rehabilitative Therapy Options National Quality Strategy Domain: Communication and Care Coordination

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient Reported Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

DESCRIPTION: The percentage of adolescents 13 years of age who had the recommended immunizations by their 13th birthday

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

Quality ID #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Quality ID #474: Zoster (Shingles) Vaccination National Quality Strategy Domain: Community/Population Health Meaningful Measure Area: Preventive Care

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient Reported Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

Note: This is an outcome measure and will be calculated solely using MIPS eligible clinician, group, or third party intermediary submitted data.

DENOMINATOR: All melanoma pathology reports for primary malignant cutaneous melanoma

Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #278: Sleep Apnea: Positive Airway Pressure Therapy Prescribed National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Quality ID #435: Quality of Life Assessment For Patients With Primary Headache Disorders National Quality Strategy Domain: Effective Clinical Care

Quality ID #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

DENOMINATOR: All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period

Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

This is a two-part measure which is paired with Measure #154: Falls: Risk Assessment.

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

DENOMINATOR: All final reports for CT imaging studies with a finding of an incidental pulmonary nodule for patients aged 35 years and older

Measure #69 (NQF 0380): Hematology: Multiple Myeloma: Treatment with Bisphosphonates National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

Quality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care

Quality ID #168 (NQF 0115): Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration National Quality Strategy Domain: Effective Clinical Care

Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE: 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40%

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID#164 (NQF 0129): Coronary Artery Bypass Graft (CABG): Prolonged Intubation National Quality Strategy Domain: Effective Clincial Care

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination

Measure #403: Adult Kidney Disease: Referral to Hospice National Quality Strategy Domain: Patient and Caregiver-Centered Experience and Outcomes

Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care

NUMERATOR: Female patients or caregivers counseled at least once a year about how epilepsy and its treatment may affect contraception OR pregnancy

Quality ID #342: Pain Brought Under Control Within 48 Hours National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Intermediate Outcome

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

Quality ID #329: Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis National Quality Strategy Domain: Effective Clinical Care

Quality ID #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient Reported Outcome High Priority

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Transcription:

Quality ID #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention and Treatment of Opioid and Substance Use Disorders 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process-High Priority DESCRIPTION: All patients 18 and older prescribed opiates for longer than six weeks duration who signed an opioid treatment agreement at least once during Opioid Therapy documented in the medical record INSTRUCTIONS: This measure is to be submitted a minimum of once per performance period for all patients being prescribed opioids for duration longer than six weeks during the performance period. There is no diagnosis associated with this measure. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. Measure Submission Type: Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website. DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration Denominator Criteria (Eligible Cases): Patients aged 18 years on date of encounter AND Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212,99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350 WITHOUT Telehealth Modifier: GQ, GT, 95, POS 02 AND Patients prescribed opiates for longer than six weeks: G9577 AND NOT DENOMINATOR EXCLUSION: Patients who were in hospice at any time during the performancall G-codes have been used. This is correctly written as M-code.e period: M1025 NUMERATOR: Patients who signed an opioid treatment agreement at least once during opioid therapy

OR Definition: Opioid Treatment Agreement a treatment agreement is a signed document between MIPS eligible clinician and patient prior to initiating Continuous Opioid Therapy (COT). This agreement should include: Potential Risks of COT Alternatives to COT Numerator Options: Performance Met: Performance Not Met: Documentation of signed opioid treatment agreement at least once during opioid therapy (G9578) No documentation of signed opioid treatment agreement at least once during opioid therapy (G9579) RATIONALE: The goal of the consent process is to assist patients to make appropriate medical decisions that are consistent with their preferences and values. In some states, clinicians are required to document this discussion, though specific requirements vary. CLINICAL RECOMMENDATION STATEMENTS: When starting COT, informed consent should be obtained. A continuing discussion with the patient regarding COT should include goals, expectations, potential risks, and alternatives to COT (strong recommendation, low-quality evidence). Clinicians may consider using a written COT management plan to document patient and clinician responsibilities and expectations and assist in patient education (weak recommendation, low-quality evidence) (p. 116). COPYRIGHT: 2015 American Academy of Neurology Institute All rights reserved. Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary coding sets should obtain all necessary licenses from the owners of these code sets. The AAN and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT ) or other coding contained in the specifications. CPT is a registered trademark of the American Medical Association.

2019 Clinical Quality Measure Flow Narrative for Quality ID #412: Documentation of Signed Opioid Treatment Agreement Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification. 1. Start with Denominator 2. Check Patient Age: a. If Patient Age is greater than or equal to 18 Years on Date of Encounter equals No during the measurement period, do not include in Eligible Population. Stop Processing. b. If Patient Age is greater than or equal to 18 Years on Date of Encounter equals Yes during the measurement period, proceed to check Encounter Performed. 3. Check Encounter Performed: a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing. b. If Encounter as Listed in the Denominator equals Yes, proceed to check Telehealth Modifier. 4. Check Telehealth Modifier: a. If Telehealth Modifier equals Yes, do not include in Eligible Population. Stop Processing. b. If Telehealth Modifier equals No, proceed to check Patients Prescribed Opiates for Longer Than Six Weeks. 5. Check Patients Prescribed Opiates for Longer Than Six Weeks: a. If Patients Prescribed Opiates for Longer Than Six Weeks equals No, do not include in Eligible Population. Stop Processing. b. If Patients Prescribed Opiates for Longer Than Six Weeks equals Yes, proceed to check Patients Who Were in Hospice at Any Time During the Performance Period. 6. Check Patients Who Were in Hospice at Any Time During the Performance Period: a. If Patients Who Were in Hospice at Any Time During the Performance Period equals Yes, do not include in Eligible Population. Stop Processing. b. If Patients Who Were in Hospice at Any Time During the Performance Period equals No, include in Eligible Population. 7. Denominator Population: a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation. 8. Start Numerator 9. Check Documentation of Signed Opioid Treatment Agreement at Least Once During Opioid Therapy:

a. If Documentation of Signed Opioid Treatment Agreement at Least Once During Opioid Therapy equals Yes, include in Data Completeness Met and Performance Met. b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 patients in the Sample Calculation. c. If Documentation of Signed Opioid Treatment Agreement at Least Once During Opioid Therapy equals No, proceed to check No Documentation of Signed Opioid Treatment Agreement at Least Once During Opioid Therapy. 10. Check No Documentation of Signed Opioid Treatment Agreement at Least Once During Opioid Therapy: a. If No Documentation of Signed Opioid Treatment Agreement at Least Once During Opioid Therapy equals Yes, include in Data Completeness Met and Performance Not Met. b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 30 patients in the Sample Calculation. c. If No Documentation of Signed Opioid Treatment Agreement at Least Once During Opioid Therapy equals No, proceed to check Data Completeness Not Met. 11. Check Data Completeness Not Met: a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation. SAMPLE CALCULATIONS: Data Completeness= Performance Met (a=40 patients) + Performance Not Met (c=30 patients) = 70 patients = 87.50% Eligible Population / Denominator (d=80 patients) = 80 patients Performance Rate= Performance Met (a=40 patients ) = 40 patients = 57.14% Data Completeness Numerator (70 patients) = 70 patients